HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) but lowers the price target from $38 to $28.
November 08, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target from $38 to $28, HC Wainwright & Co. maintains a 'Buy' rating on Iovance Biotherapeutics.
The news is directly related to Iovance Biotherapeutics and is likely to influence investor sentiment. While the lowered price target might be seen as a negative signal, the maintained 'Buy' rating indicates that the analyst still sees potential in the stock. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100